SUVEN LIFE SCIENCES LTD. SHARE PRICE [LIVE]

BSE: INE495B01038   NSE: SUVEN   SECTOR: Pharma

OPEN YOUR FREE DEMAT ACCOUNT AND START TRADING SEAMLESSLY
Already an existing customer? - Login Now!
NSE
71.65
Change:
BSE
72.00
Change:
NSE
BSE Click here to view BSE data
Loading, Please wait...
Error in Fetching Data, Please retry later.
No data available.
Open:
High:
Low:
MKT Cap:
52-wk High:
52-wk Low:
Prev close:
P/E:
Div yield:

Fundamental analysis

Quality
Valuation
0 250 500 750 1 000
Financial trend

What is not working for the company?

What is working for the company?

Stock
Sector
Sensex
Name Mar 21 Dec 20

Similar Stocks

Return Calculator

This tools helps you project your potential return on investments for the given stock, for a specified amount over a per-defined period of time.

If I had made LUMPSUM investment of ₹ 1,00,000

in SUVEN LIFE SCIENCES LTD.

Months ago

My investment would be worth ₹ 1,41,900 with a Gain of 41.90 %

SUVEN News

Frequently Asked Questions

What is the Share price of SUVEN LIFE SCIENCES LTD. (SUVEN)?

SUVEN LIFE SCIENCES LTD. (SUVEN) share price as of August 5, 2022, on NSE is Rs 71.65 (NSE) and Rs 72.00 (BSE) on BSE.

Can I buy SUVEN LIFE SCIENCES LTD. (SUVEN) shares?

Yes, You can buy SUVEN LIFE SCIENCES LTD. (SUVEN) shares by opening a Demat account with Angel One.

How do I buy SUVEN LIFE SCIENCES LTD. (SUVEN) from Angel One?

SUVEN LIFE SCIENCES LTD. (SUVEN) share can be brought through the following modes:
  1. Direct investment: You can buy SUVEN LIFE SCIENCES LTD. (SUVEN) shares by opening a Demat account with Angel One.
  2. Indirect investment: The indirect method involves investing through ETFs and Mutual Funds that offer exposure to SUVEN LIFE SCIENCES LTD. (SUVEN) shares.

In which sector do SUVEN LIFE SCIENCES LTD. (SUVEN) belong?

SUVEN LIFE SCIENCES LTD. (SUVEN) belongs to Pharma.

About SUVEN

Today's live share price for SUVEN LIFE SCIENCES LTD. is NSE: ₹ 71.65, BSE: ₹ 72.00 with a current market capitalization of .

Incorporated in Mar.'89 as a private limited company, Suven Pharmaceuticals (SPL) was converted into a public limited company in Jan.'95. It was promoted by Jasti Sudha Rani and Jasti Venkateswarlu, who is the present managing director. In Mar.'95, SPL came out with a public issue of 9.8 lac equity shares at a premium of Rs 40 aggregating Rs 4.9 cr to part-finance the company's project for the manufacture of bulk drugs and drug intermediates and meet long-term working capital requirements totalling to Rs 6.43 cr. The company manufactures bulk drugs and drug intermediates -- theophylline, caffeine, nitroso compound, cyanoacetic acid, etc. SPL has a sizeable export turnover through the export of drug intermediates to Germany, Switzerland, Israel, Europe, etc. During 1999-2000, the company has acquired a small pilot plant in Jeedimetla Industrial Estate,Hyderabad. During 2000-01, the company has registered a most remarkable record. The total sales of the company during 2000-01 has registered a growth of 71% over the previous year.The Profit After Tax(PAT) has also registered a growth of 325% over the previous year. The company has successfully achieved the re-certification of ISO 9002 during the year 2000-01. The company is planning to Modernize & Upgrade its R & D at Jeedimetla Industrial Estate.

Read more